Ocular drug delivery
Blindness and visual impairment affect millions of people worldwide and have a very important impact on the quality of life. The main causes in middle-income and industrialized countries are represented by glaucoma, age-related macular degeneration (AMD) and diabetic retinopathy. These pathologies are prevalent in the elderly and in diabetic patients and, because of aging population and lifestyle change, the prevalence of these diseases is expected to rise significantly. Beside these, other pathologies with inflammatory, infective, genetic or degenerative causes involve different ocular structures.
In the past years, the introduction of new pharmacological strategies involving proteins (such as anti-vascular endothelial growth factor -VEGF -monoclonal antibodies -mAb -) has significantly changed the clinical outcome of some of these diseases, such as wet AMD. The continuous improvement of understanding the molecular basis of the pathologies will probably increase the number of possible drug candidates in the next years.
Despite the new available molecules, drug administration to the eye remains a difficult task, due to the peculiar structure of this organ and the presence of numerous barriers, static and dynamic, protecting the internal tissues. [1] ). Figure 1 illustrates the structure of the human eye [1] . The eye bulb has three concentric tunics, one external, fibrous layer comprising the cornea and sclera; one intermediate vascular tunic comprising the iris, ciliary body, and choroid; and one internal, nervous tunic or retina. Additionally, the eye can be roughly divided into two segments, separated by the lens: the anterior segment (conjunctiva, cornea, anterior and posterior chambers containing aqueous humor, iris and lens) and the posterior segment (vitreous body, retina, choroid and posterior sclera). Anterior and posterior chambers are filled with the aqueous humor, while the vitreous cavity is filled with a gel-like fluid called vitreous humor. The conjunctiva is a transparent mucous membrane that covers the inner surface of the eyelids and the surface of the anterior sclera; it is continuous with the cornea and the junctional region is called limbus. The epithelium of the cornea and of the conjunctiva are covered by mucins (secreted mucins -both gel forming and small soluble -and cell surfaceassociated mucins) playing a lubricant and protective role and contributing to the hydrophilic character of wet-surfaced epithelia [2, 3] .
Ocular anatomy

Figure 1. Schematic representation of human eye (with permission from
For the treatment of anterior segment diseases and for the management of glaucoma, the application of eye drops, gels or ointments in the conjunctival fornix and/or on the ocular surface, is the simplest and generally preferred administration route. However, this route is characterised by low compliance (often due to the high administration frequency required) and low drug bioavailability (generally lower than 5%). The latter is due to the short residence time of the formulation on the ocular surface and to the low permeability of the cornea. The cornea is an avascular tissue consisting of a collagenous layer (stroma) enclosed by an anterior epithelium and a posterior endothelium. The epithelium, with tight junctions in its superficial layers, represents the main barrier toward the penetration of drugs.
The posterior segment of the eye is not accessible to drugs applied topically on the cornea or in the conjunctival cul-de-sac; on the other hand the efficacy of systemic administration is hindered by the presence of the blood-retinal barrier (BRB) and limited by possible systemic toxicity. BRB is composed by two distinct barriers, located in different regions: the outer BRB is located in the retinal pigment epithelium (RPE), while the inner BRB is located in the endothelium of retinal microvasculature.
For these reasons, the intravitreal injection (i.e. direct injection of the drug in the vitreous body) is, at present, the most efficient option for drug administration to the retina.
However, due to the serious side effects, other, alternative and less invasive administration routes are in use or under investigation: trans-scleral (comprising subconjunctival, sub-Tenon, peribulbar, posterior juxta-scleral and retrobulbar injections), intra-scleral and subchoroidal delivery are among them. Using these routes the drug is not directly available to the retina, but must diffuse across the underlying tissues, overcoming static (sclera, choroid, Bruch's membrane, RPE) and dynamic barriers, such as blood and lymphatic flux and choroidal circulation.
It is worth mentioning that the integrity, structure and efficiency the different barriers involved in ocular drug delivery can change as a function of two important factors: aging and disease. Since aging is the most important risk factor for several eye diseases, the changes produced by the two causes tend to overlap. Disease-induced barrier weakening or disruption had been shown to influence deeply drug distribution. When the epithelial barrier of the cornea is compromised by the presence of corneal neovascularization (NV), for example, the topical application of a mAb can be effective in the treatment of anterior segment diseases [5] . Concerning the posterior segment, as an example, celecoxib accumulation in retina and vitreous, following periocular administration, was higher in diabetic than in healthy rats, because of the disruption of BRB produced by diabetes [6] .
Nanoparticles and eye
Nanomedicines are medicinal products with at least one component at nano-scale size.
Until a few years ago the size was the only classification criterion and the nano range was defined as the interval 1-100 nm. Presently, in the EMA website, nanotechnology is defined as "the use of tiny structures -less than 1,000 nanometres across -that are designed to have specific properties", significantly widening the size range and emphasizing the role of nanometric dimension on the clinical advantages (i.e. specific organ/tissue distribution), more than the sole effect on chemical and physical properties (generally observed for materials with size below 100 nm) [7] . Similarly, the FDA has recently released a Guidance for Industry where the nanotechnology definition is extended to materials or end products "engineered to exhibit properties or phenomena, including physical or chemical properties or biological effects, that are attributable to its dimension(s), even if these dimensions fall outside the nanoscale range, up to one micrometer (1,000 nm)" [8] .
Numerous and diverse are the contributions given (or that could be given in the future) by the nanotechnologies to the treatment of eye diseases [9] : sensors for biophysical measurement (such as wireless contact lenses for IOP -intra ocular pressuremeasurement), biosensors for diagnostic and theragnostics [10] , prosthetics (i.e. sight restoring therapy by retinal cell stimulation), regenerative nanomedicine [11] and nanocarriers, such as nanoparticles, liposomes and other vesicular carriers, micelles and dendrimers, for the delivery of drugs, peptides and genes. The use of nanocarriers in ocular drug delivery can address some of the the main unmet medical needs, such as the low bioavailability of antibiotics, anti-inflammatory and antiviral drugs, the treatment of retinal and corneal NV, degenerative diseases, hereditary retinal disorders and tumors.
Additionally, refractive cornea surgery, healing process in the eye, gene therapy, regenerative medicine (growth factors delivery) could highly benefit from nanocarriers.
The possible advantages of using nanocarriers are due to the special physical and/or chemical properties produced by size reduction, that differ from those at macroscopic scale. In particular, in the case of nanocarriers for pharmaceutical use the most important property is the increased surface area-to-volume ratio. This leads to an increasing dominance of the behaviour of atoms on the surface of a particle, affecting all the surface phenomena and the interactions with other materials, such as those present in the biological environment in which the particle finds itself after administration. In this perspective, it is clear that size, shape, surface charge, surface coating and functionalization, as well as the nature of the constituent material, highly influence nanocarriers performance and biocompatibility. These characteristics can often be controlled and tuned thanks to parameters variation in the preparation procedures.
In general, NPs have been proposed as carriers to protect the encapsulated drug from degradation, control drug release, increase residence time on the ocular surface, facilitate the transport of drugs into cells and finally increase drug bioavailability. Additionally, due to the very small dimensions, NPs can be administered through any of the routes previously mentioned.
However, the usefulness of this carriers in ocular drug delivery is not "universal" and the benefits depend upon several factors, such as the ocular pathology involved (the different localization inside the ocular bulb but also the target that can be both extra and intra cellular), the administration route and the characteristics of the drug (in particular its potency, its physico-chemical characteristics and its stability in a biological environment).
Furthermore, some issues about NPs for ocular delivery must be highlighted. When considering the ocular anatomy, for instance, it is evident that there are important limitations on the volumes that can be administered. For example, maximum one drop (50 µl) is considered suitable for topical application, 20-100 µl for intravitreal injection, 500 µl for subconjunctival injection, 35 µl for intra-scleral injection and 35-100 µl for suprachoroidal delivery [12, 13] . It follows that, in order to administer a significant amount of drugs, NPs should have an high drug loading (not easy to achieve) and/or be highly concentrated, especially in the case of drugs administered at high doses. NPs are not always physically stable and can aggregate when present at high concentration; as a consequence, despite the immune privilege of the eye, inflammatory and/or immunostimolatory events could occur. The issues related to nanomaterial toxicity are a hot topic, that is presently the subject of numerous paper and public discussions.
Reflection papers can be found in the website of regulatory agencies, but very few data are available on the specific toxicity on ocular tissues. NP toxicity is related not only to the polymer used (for instance, PLGA -Poly(Lacti-co-Glicolic) Acid -is already used for the intravitreal implant Ozurdex ® and demonstrated good tolerability), but also to the size that can promote cell-uptake, with possible accumulation inside the retinal cells and damage of cellular function [14] .
Administration routes
Topical administration
Topical administration is used when the target is the conjunctiva, the cornea or the anterior and posterior chambers. The main advantage that can be achieved using nanoparticulate carriers is an improved drug bioavailability in the anterior chamber, generally due to increased residence time and, in some cases, enhanced trans-corneal permeability.
The increase in residence time in the cul-de-sac and on the ocular surface can be obtained by using mucoadhesive excipients. The presence of mucoadhesive polymers allows NPs to adhere to the pre-corneal or conjunctival mucus layer by non-covalent bonds and to remain on the ocular surface for as long as mucin is present. This can ultimately lead to a reduction of the frequency of drug administration and thus increase patient compliance. A detailed review on this topic has been recently published [15] . When the constituting polymer is not mucoadhesive, NPs can be superficially coated with mucoadhesive polymers such as chitosan, hyaluronate or alginate [16] .
The improved drug bioavailability reported using nanocarriers can also be ascribed to an enhanced trans-corneal transport, due to NPs permeation. This phenomenon has been reported with different polymers and/or coatings and has been ascribed to different phenomena: opening of tight junction in the corneal and conjunctival epithelia, so as to improve the transport across the paracellular pathway, NPs endocytosis, cellular lysis due to NP degradation products [17] [18] [19] .
Apparently, the possibility for NP to cross the epithelial layers depends upon NP size and surface properties such as charge, composition (hydrophilicity/hydrophobicity) and coating/functionalization. One of the most studied polymers is chitosan, a natural polysaccharide characterized by biocompatibility, biodegradability, mucoadhesion, and the ability to transiently enhance the permeability of mucosal barriers [20] . At the same time, In the literature several recent reviews are present on the use of nanoparticulate carriers for anterior segment diseases. Cholkar [22] analyses in particular the results related to anti-inflammatory drugs, while a recent review from Gonzalez et al. provide an overview of the possible use of nanotechnology in corneal NV [23] . Kim [24] and Pita-Thomas [25] describe the results obtained and the potential implications for the glaucoma treatment.
Intravenous administration
Intravenously administered NPs have been studied to target and treat posterior segment diseases, based on the assumption that they can pass through the BRB. Sakai [26] demonstrated, in an experimental uveoretinitis model in rats, that betamethasone loaded in PLGA NPs accumulated in the retina after intravenous injection and was more effective than when injected alone. Kim et al. found that intravenously administered gold nanoparticles can cross the BRB depending on particle size. In particular, 100 nm NPs were not found in the retina, while 20 nm NPs passed the BRB and were detected in all retina layers [27] . The possibility to cross the BRB is often related to the presence of ocular diseases. For instance, PLGA NPs loaded with recombinant Flt23k intraceptor plasmid for gene therapy were injected intravenously in a rodent model of laser-induced choroidal neovascularization (CNV): NPs accumulate in the neovascular eye, but not in the control eye, indicating that drug ocular bioavailability following intravenous injections depends upon the integrity of BRB. These NPs were also functionalised with the tripeptide arg-gly-asp (RGD) that can bind integrin receptors, and/or with transferrin that can bind transferrin receptor on the retinal cells surface. In both cases the surface functionalization increased retinal uptake and inhibit the progression of the disease [28] .
Intravitreal injection
The main goal of the intravitreal injection is to deposit the drug in close contact with the target site (retina/RPE/retinal blood vessels/vitreous). Despite its efficacy, this route of administration has significant drawbacks and risks, such as bleeding, pain, infection, IOP increase and retinal detachment. Additionally, for the treatment of chronic diseases such as AMD, monthly intraocular injections are needed, with a corresponding increase in the risk of side effects. Another limitation of this dosage regimen is an initial very high drug concentration in the vitreous that can be responsible for important side effect, in particular in the case of corticosteroids.
In order to reduce these problems, intravitreal implants have been proposed [29, 30] . In this perspective, NPs can be of help since they can be easily injected with a conventional needle and form a reservoir inside the vitreous; due to the small size they should not interfere with the vision (or maybe limit the blurring of vision compared to microparticles); they protect the drug from the environment, increasing the drug half-life in the vitreous and can control the release of the drug thus avoiding peak and valleys in the vitreous concentration (even though they are less efficient in controlling drug release compared to microparticles). In this way they could also reduce the amount of drug that needs to be administered and possibly the volume to be injected (thus reducing IOP increase).
An additional property attributed to nanoparticulate carriers is the ability to cross cell [37] . The importance of surface chemistry on intravitreal movement was evidenced by different authors [38] [39] [40] . Kim found that cationic nanoparticles diffuse more slowly in the vitreous than anionic NPs (probably because of a ionic interaction with hyaluronan) and that the positive charge hinders movement more than the size. This data was also confirmed using self assembled polymeric NPs in a murine model: strongly cationic PEI (polyethylenimine) nanoparticles interacted tightly with the vitreous matrix, while cationic glyco chitosan NPs penetrated the vitreous and reached the inner limiting membrane but could not cross it. On the contrary anionic NPs of hyaluronic acid and human serum albumin (HSA) showed the ability to penetrate across the whole retina and accumulate in the RPE [39] .
The importance of both size (100-1000 nm) and surface chemistry was also investigated ex vivo using polystyrene (PS) amine-modified (cationic PS-NH 2 ), carboxy-modified (anionic PS-COOH) and PEG coated (not charged, PS-PEG) nanoparticles [41] . A summary of the results obtained is illustrated in Figure 2 and highlights: (i) steric hindrance for 1000 nm particles; (ii) electrostatic hindrance for positively charged NPs; (iii) hydrophobic hindrance for concentrated negatively charged NPs; (iv) free diffusion for nonadhesive (PEG coated) NPs smaller than 1000 nm. These results, obtained ex vivo using real-time multiple particle tracking (MPT), can be of great help in the future design of NPs for intravitreal delivery.
Figure 2. Schematic illustration of the effect of size and surface characteristics on NPs transport in the vitreous. Hydrophobic, electrostatic and steric effects can hinder particle transport in vitreous meshwork. Particles with size ≥ 1000 nm were immobilized due to steric hindrance; dilute PS-COOH NP (≤ 200 nm) diffused freely within vitreous, while concentrated PS-COOH NP aggregated because of hydrophobic interactions. 500 nm PS-COOH NP was greatly hindered due to both hydrophobic and steric effects; PS-NH 2 NP aggregated because of electrostatic interactions with the negatively charged vitreous; nonadhesive PS-PEG NP diffuse freely within vitreous if their size was no larger than 500 nm.
From [41] with permission.
Trans-scleral, intra-scleral, suprachoroidal administration
These new administration routes have been proposed as an alternative to intravitreal injection to reach the posterior segment of the eye without the side effects and risks of direct injection. In the trans-scleral delivery, the drug must cross the whole sclera to reach the underlying tissues; this happens when the drug is applied in the conjunctival fornix, but also in case of subconjunctival, sub-Tenon, peribulbar, posterior juxta-scleral and retrobulbar injections. NPs can be used in these administration routes mainly to create a drug reservoir in order to control and sustain the delivery of drug for long periods, thus reducing administration frequency. NPs should in this case be retained as long as possible at the injection site so as to deliver all the loaded dose However, apparently, microparticles (MPs) seems to be a better solution, because of the higher drug loading, lower burst effect and better control of drug release [42] . Additionally, MPs are characterized by a slower clearance in the periocular space, compared to NPs. The fate of nanoparticles (20 and 200 nm and 2 µm carboxylate polystyrene NPs, negatively charged) has been investigated after periocular administration and the 20 nm NPs were rapidly cleared by blood and lymphatic circulation, while 200 nm and 2 µm particles was still found in the periocular tissues after 60 days [43] . The fast clearance of small NPs was also recently confirmed by
Feng et al. using pRNA NPs 10 nm in size [44] , while a significantly longer retention was demonstrated by latanoprost-loaded NPs of 80 nm that sustained drug level in the aqueous humor for at least 6 days [45] .
In the intra-scleral delivery, a drug reservoir is injected in the sclera thickness using an in vivo to New Zeland white rabbits, remained in the suprachoroidal space for at least 2 months without any sign of clearance [12, 47] .
Nanoencapsulation of therapeutic proteins
Proteins represent nowadays very important therapeutic tools. The total global market for protein-based therapies is growing very fast, with mAbs dominating. At present, more than 240 mAb and 120 proteins are in clinical trials or under development for the treatment of cancer, immune disorders, infections, and degenerative diseases [48] . Proteins are used also for the treatment of several eye diseases. Together with the well known bevacizumab, ranibizumab and aflibercept, anti-VEGF agents for neovascularization-related eye diseases, other proteins are in use or under development [49] . (ii) they can have stability problem (aggregation) and/or can be degraded by enzymes naturally present in the body;
(iii) all protein therapeutics are potentially immunogenic in patients;
(iv) they are generally very expensive.
Nanoencapsulation of peptides and proteins could be of help for solving some of the previously mentioned issues. NPs can protect the drug from metabolic activity that is present in ocular tissues [51] and in the vitreous body [52] thus prolonging their half-life, and can control and sustain the release of the active. These actions will also reflect in a reduction of the required dose, with a possible positive impact on costs. Finally, NPs can promote drug retention on ocular surface (mucoadhesion), penetration across epithelia and cell internalization.
However, the complications related to protein nanoencapsulation cannot be neglected.
The problems are strictly linked to the encapsulation method used, nevertheless, some general consideration can be made. First of all the method chosen must preserve protein structure and activity; this is a very delicate aspect, also considering the extensive use of heat and/or organic solvents in NPs production. Sometimes, to preserve drug activity, the therapeutic protein is loaded after the nanoparticle/liposome production procedure. Due to the high drug cost it is very important to optimize the production procedure so as to increase as much as possible the encapsulation efficiency. In general, it is known that the encapsulation efficiency (EE) is inversely related to the size of the particles (the procedure and the polymer being the same, EE is generally higher for MPs compared to NPs). In analogy, by reducing the size of the particles, also the control of the release is reduced, with the appearance of an important burst effect. Together with EE, also the drug loading (LC) is of the outermost importance, in particular in the case of highly dosed protein, so as to reduce as much as possible the amount of excipient to be used. This aspect is significant, also considering the very small volumes that can be delivered in the case of ocular administration (see section 2). All these consideration justify the reason why at the moment no protein-loaded nanoparticles are present on the market, also in the case of ophthalmic application.
In the next paragraphs, a review of scientific works describing ocular delivery of NPs containing therapeutic or model proteins is presented. The data have also been summarised in Table 2 . It is worth noting that all the paper found on this subject are very recent and demonstrate a growing interest on this subject driven by the recent discovery of the molecular basis of some ocular pathologies, by the increased possibility of protein production thanks to the DNA recombinant techniques and by the undeniable relevance and impact that sight problems have in our society.
Anti-angiogenic drugs
Bevacizumab (Avastin Liposomes loaded with bevacizumab were prepared following the dehydratationrehydratation method, using phospholipid and cholesterol in molar ratio 1:1. Bevacizumab was added to blank multilamellar liposomes and the mixture was freeze-dryied: the encapsulation efficiency was 45% and bevacizumab remained stable during the preparation procedure. The intravitreal injection of bevacizumab-loaded liposomes in rabbits in vivo, allowed to achieve a higher drug concentration-time curve and a slower clearance compared to the antibody solution [53] .
The preparation of PLGA NPs using the emulsification/solvent evaporation technique is reported by different authors [54] [55] [56] [57] [58] . Pan has described bevacizumab containing NPs with an average size of 819 nm and a LC of 2.2%. Inside NPs, which were evaluated for the treatment of CNV in a rat model, the mAb retained its activity [55] . Concerning the antibody stability during the preparation procedure, Varshochian reported the positive effect exerted by albumin, which, at the same time, can be of help also in the control of drug release [56] . Hao and colleagues have prepared bevacizumab-PLGA NPs, which, unlike previous examples, were intended for trans-scleral delivery [57] .
In order to avoid one of the more important drawbacks of NPs, i.e. the limited control of drug release and the presence of a burst effect, a system composed of nanoparticles entrapped in porous MPs was prepared and evaluated. In particular, bevacizumab-coated PLA NPs were encapsulated into porosyfing PLGA microparticles using supercritical carbon dioxide [59] . Supercritical carbon dioxide enabled the rapid expansion of PLGA, while produced no effect on crystalline PLA: the final entrapment of PLA NPs into PLGA microparticles was confirmed by SEM images (Figure 3) . After complex formation, the NPs, 150 nm in size, were prepared by nanoprecipitation and had a maximum entrapment of approx. 85% [62] . HIP complexation has been previously described by the same research group, who developed PLGA NPs loaded with BSA [63] or lysozime [64] , chosen as model proteins, in order to set-up the preparation of NPs able to guarantee not only the sustained delivery of the protein loaded, but also to preserve its therapeutic activity.
In 2011 FDA approved the use of aflibercept, a fully human recombinant fusion protein that exerts an anti-angiogenic activity by "entrapping" VEGF and thus preventing the interaction with VEGFR. From a clinical point of view, aflibercept has demonstrated a comparable efficacy to ranibizumab [65] ; however, to date no data concerning aflibercept loading NPs are available.
Two recent examples of new anti-angiogenic peptides are C16Y, a 1.6 kDa integrinantagonist peptide with hydrophilic properties, active in blocking integrins involved in NV process, and SP6001, a serpin-derived peptide negatively charged. C16Y was successfully encapsulated in polylactic acid/polylactic acid-polyethylene oxide (PLA/PLA-PEO) NPs (approximately 300 nm, negatively charged -38 mV), in order to improve the peptide intravitreal half-life as well as retinal penetration. In vivo studies performed using a model of NV in rats, demonstrated the higher efficacy of C16Y-loaded NPs compared to the peptide solution [66] . For SP6001 intravitreal delivery, poly(beta-amino ester) (PBAE), a cationic polymer, was used to obtain self-assembled polymer-peptide NPs (119 nm), that were than encapsulated inside PLGA microparticles (approx 10 µm) to extend peptide release [67] . In vitro, the system showed approximately zero order release of SP6001 for more than 6 months; in vivo, after injection in mice with CNV, angiogenesis decreased for at least 3 months: a better result than for peptide alone, which controlled the pathologic condition for less than one month.
Neuroprotective factors
Basic fibroblast growth factor (bFGF) is a neuroprotective agent involved in the prevention of photoreceptors degeneration. In order to protect the peptide and avoid complications associated to the direct injection of naked bFGF inside the ocular bulb, the protein was loaded on gelatin NPs. bFGF was incorporated by dropping a drug solution on freeze-dried gelatin NPs [68] . The intravitreally injected NPs (approx. 600 nm in size) were retained inside RPE and retina for at least 8 weeks after administration, allowing a sustained release of bFGF, which, being direct towards photoreceptors, has inhibited their apoptosis ( Figure 4 ).
Figure 4. Confocal images of the retina of RCS rat 6 (A) and 8 (B) weeks after injection of rhodamine-labeled bFGF-NPs. NPs are present in the inner plexiform layer (IPL), and in the outer nuclear layer (ONL) at 6 weeks. At 8 weeks after injection, the NPs were in the inner nuclear layer (INL), ONL, and RPE apical surface. Arrowheads: NPs. Scale bar, 50
μm. From [68] with permission (to be obtained).
A small signal peptide, made only of serine, threonine and tyrosine, was conjugated to low molecular weight chitosan NPs, and proposed to treat macular degeneration thanks to its ability to act as a transduction agent inside RPE cells [69] . To prevent RPE cells apoptosis, recently Wang and colleagues proposed the use of a mini-peptide, made of 20 amino acids, derived from the heat shock protein αβ-crystallin and having chaperone properties [70] . Despite its neuroprotective activity, the small size makes the peptide highly exposed to intraocular degradation, with consequent very low viability. In order to minimize this aspect, an innovative bioengineering approach involving NPs was adopted. The minipeptide was fused to an elastin-like polypeptide (40 kDa), used as carrier protein. This fusion-construct, expressed in E. coli using the DNA recombinant technique, self-assembly into small NPs following a temperature-dependent process. The resulted NPs, about 30
nm in size, were tested in human RPE cell culture, in which an oxidative stress was induced. The anti-apoptotic activity exerted by mini-peptide was preserved; furthermore, cell internalization, probably via clathrin-mediated endocytosis, took place.
Anti-inflammatory agents
Among anti-inflammatory agents, the introduction of anti TNF-alpha in ophthalmology for the treatment of uveitis and retinal diseases represents a recent fact and several studies are ongoing in order to demonstrate their efficacy and safety [71] . Efficacy and safety have been assessed for adalimumab and infliximab, two IgG mAbs, while the soluble TNF receptor fusion protein etanercept is no longer a candidate because of its tendency to worsen uveitis [72] . Among others anti TNF-α, certolizumab and golimumab have recently been approved for systemic use but they have not yet been tested in ocular inflammation affections [73] .
Since the systemic administration of TNF-α inhibitors can result in several side effects (chiefly, an increase tendency to develop infectious diseases) [71] , an alternative treatment based on local application is preferred.
At the present time no literature data are available concerning ophthalmic NPs containing infliximab; on the contrary, the development of adalimumab NPs has been reported.
Adalimumab (Humira
TM
) is a 148 kDa recombinant human IgG mAb, approved for the treatment of several rheumatic diseases (among which, rheumatoid arthritis and Crohn's disease) by means of subcutaneous injection [74] . It binds both soluble and membrane forms of TNF-α, a pleiotropic cytokine involved in the development and maintenance of inflammatory processes having an autoimmune origin. In ophthalmology, adalimumab has displayed its ability in controlling and preventing anterior and refractory uveitis as a consequence of subcutaneous administration [75] .
Romero et al. have developed
PolyElectrolyte Multilayers (PEMs) PLGA) NPs to control adalimumab delivery [76] .
PolyElectrolytes used were alginate (negatively charged) and polylysine, which has a polycation nature. Blank PLGA NPs were prepared using the emulsion/solvent evaporation method and were then covered by using the layer-by-layer (LbL) technique. The positively charged antibody was added to alginate, in order to obtain a negatively charged complex (zeta potential approx. -25 mV). Then, polylysine and antibody/alginate complex were alternatively layer-by-layer deposited onto NPs up to 11 or 25 levels, in strictly controlled conditions of pH and ionic strength. Since the outer layer was always polylysine, the zeta potential of the final PEMs NPs corresponded to +13 mV. In vitro adalimumab release in PBS followed a first order kinetic after an early burst effect. After 1 and 5 days, the percentages of antibody released were respectively of 50% and 60-70%. Even if the described NPs have been proposed for local delivery, they have not been yet tested specifically for ocular application; however the preliminary data suggest their potentiality in ophthalmologic field, also for the delivery of different proteins.
Vasoactive intestinal peptide (VIP) is an endogenous ocular peptide, consisting of 28 amino acid residues, with recognized immunomodulatory properties. Peptide-loaded liposomes (between 300 and 600 nm in size) were prepared by thin layer hydration and loaded by lyophilization-rehydration. These carriers were developed in order to protect VIP against degradation, when intravitreally injected in rats with endotoxin-induced uveitis [77] .
The study demonstrated the effectiveness of liposomes in controlling VIP release as well as their ability in protecting the peptide for 14 days. In this case the presence of the nanocarrier is essential to ensure the stability of VIP, which, when directly injected inside vitreous, is rapidly degraded and thus unable to produce a therapeutic effect. Recently, fluorescently labelled BSA was also loaded on silk fibroin NPs [80] and fibroin NPs demonstrated their stability in presence of US [80] . The work is a very good example of how the combination between NPs and a physical enhancer can lead to targets not achievable until few decades ago.
Model proteins
Carrier proteins
Proteins can be used as excipients for the preparation of NPs and have demonstrated to be suitable for the delivery of both small and high molecular weight active ingredients.
Protein nanocarriers allow to preserve drug activity, to sustain drug release and enable the targeting to specific substrates; in fact, proteins are easily amenable to modifications to allow the attachment of targeting ligands. Proteins, being in most cases of natural origin,
show high biocompatibility and biodegradability, are well characterized and may be considered safe enough, at least from a general point of view. The natural origin can also be a drawback because of the possible immunogenicity (particularly due to aggregation), the high variability and sometimes the need to remove from the starting material all the contaminants that may produce toxicity in human [81] as, for example, the possible presence of transmissible spongiform encephalopathy vectors in bovine gelatin [82] .
Despite these limitations, the use of protein as excipients for NPs preparation have interesting perspectives. It is worth mentioning, for instance, that one of the more successful examples of nanoparticle formulation on the market is made of albumin (Abraxane ® ).
Nanoparticles have been prepared using both water-soluble (serum albumin) and waterinsoluble proteins (such as zein and gliadin). The next paragraphs review the use of proteins as nanocarriers for ocular drug delivery.
Fibroin is a high MW protein, composed of a 25 kDa light chain and a 325 kDa heavy chain, joined by a disulfide bond; the two chains are non-covalently connected to P25, a 25 kDa glycoprotein [83] . Fibroin is extracted from cocoons of Bombyx mori (mulberry silkworm) and purified from sericin, a protein coating single fibroin filaments. Silk fibroin has been used to prepare ocular NPs via anti-solvent precipitation method [80] . In vivo mucoadhesion tests performed on rabbit demonstrated the ability of the silk fibroin NPs to quickly adhere on sclera surface, while, as previously reported in the present paper, in vitro permeation studies confirmed the diffusion enhancement of BSA loaded in fibroin NPs, particularly when US were associate, with respect to BSA solution.
Being BSA highly versatile, it is used as a model of therapeutic protein (see section 4.4), but also as a carrier protein. Especially thanks to their biocompatibility and the biodegradability, many examples of albumin NPs for ocular use can be found in the literature. Most of them are intended for topical application and are loaded with small drugs such as antiglaucoma agent pilocarpine [84] , anti-inflammatory compounds, such as hydrocortisone [85] , aspirin [86] , and meloxicam [87] , antiviral drugs like acyclovir [88] .
Zimmer and collaborators used a slightly modified desolvation method to prepare hydrocortisone-loaded albumin NPs, starting from a micellar solution of the lipophilic drug.
The NPs obtained, having a size ranging between 100 and 300 nm, displayed an EE up to 70% and demonstrated their efficacy in both in vitro and in vivo studies [85] . Following the same method, also albumin NPs loaded with the hydrophilic pilocarpine were prepared and characterized [84] . In this case, the use of NPs instead of the solution has increase 1.5-1.9-times the miotic effect, with a consequent significant reduction of the IOP.
Desolvation method was used by Noomwang to prepare bovine albumin NPs of spherical shape and average size of 130 nm [88] . Acyclovir was successfully loaded with 20% of EE and 1% of LC.
Using the desolvation based coacervation technique Das [86] prepared aspirin-loaded albumin NPs having a size of 65 nm, with low polydispersity index, and a positive zeta potential (+25 mV). The average drug entrapment was 80% and in vitro studies showed the ability of NPs to release the NSAID for as long as 3 days, without any burst effect.
Furthermore, DLS analysis demonstrated the stability of the lyophilized NPs for at least 6 months. Based on their experimental data, the authors hypothesized the use of the abovementioned NPs, intended for topical administration, also for the treatment of posterior segment affections.
Thanks to the optimal tolerability, albumin represents also a suitable carrier for NPs intended to be administered intravitreally. NPs injected inside the ocular bulb enable a sustained release of the active inside the vitreal chamber, with consequent reduction in the number of injections needed. The hydrophilic drug ganciclovir, antiviral treatment of cytomegalovirus retinitis, was firstly loaded in albumin particles by El-Samaligy, who obtained spherical particles having an average particle size of 1.2 μm [89] . Afterwards, other several successful attempts were done in order to optimize the nanoparticulate formulation, by using the coacervation method and loading ganciclovir not only inside NPs, but also on their surface [90] : the entrapment efficiency resulted 40% for loaded NPs and 20% for those with the drug adsorbed on the superficial layer. The presence of ganciclovir on NPs surface resulted in a more effective antiviral activity since, once NPs are internalized by cells, the drug is released in a more rapid way [91] .
As antiviral activity against human cytomegalovirus can be explicated also by antisense oligonucleotide, both phosphodiester and phosphorotioate oligonucleotides were either adsorbed on the surface or incorporated inside albumin NPs [92] . The entrapment efficiency was approx. 74% for phosphodiester while 59% in the case of phoshorotioate, reflecting the different affinity of the two oligonucleotides for albumin. The average size (250 nm) as well as the charge (-22 mV) were independent from the loading method and oligonucleotide type; [92] . Even if the NP preparation procedure preserved oligonucleotide hybridization capability, the simple adsorption onto NPs surface does not efficiently protect the oligonucleotide against enzymatic degradation. However, BSA NPs improved the internalization of oligonucleotides inside cells.
In order to deliver more effectively and to protect genetic material intended for ophthalmic treatment, some authors described the use of HSA NPs as non-viral vector for both intravitreal [38, 93] and intracorneal [94] administration. HSA NPs enabled the sustained release of the gene loaded and were rapidly uptaken from cells via receptor-mediated endocytosis. Furthermore, they demonstrated complete lack in cytotoxicity [93] . Human serum albumin NPs showed their safety also with regard to corneal keratocytes [94] .
Gelatin is a composite of purified protein fractions derived from porcine and bovine collagen, available as type A gelatin, obtained by partial acid hydrolysis, type B gelatin, produced by partial alkaline hydrolysis, or a mixture of the two [95] . Gelatin is largely used in pharmaceutical technology as gelling agent, film-forming agent, viscosity enhancer and different grades of gelatin, with different particle size, molecular weight and other properties, are commercially available [95] . As nanocarrier, gelatine offers, among otherpolymers and biopolymers, a peculiar characteristic, which consists in the polyampholyte nature, due to the presence of cationic and anionic group together with hydrophobic groups [96] .
Thanks to the high biocompatibility shown, several examples of gelatin NPs intended for ophthalmic use can be found in the literature. Gelatin allows the preparation of both positive and negative NPs, with smooth surface and spherical shape [97] , to be administered either topically [97, 98] or intra-vitreally [68] and loaded with small molecules [98] as well as with high molecular weight compounds [68] . In order to increase ocular bioavailability of pilocarpine HCl and hydrocortisone, two drugs with different solubility, they were encapsulated in gelatin NPs via desolvation method [98] . NPs encapsulating pilocarpine showed that the type of gelatine as well as pH conditions did not affect the particle size and charges, that resulted slightly negative; on the contrary, hydrocortisone
NPs showed different zeta potential, as a consequence of use of different gelatine type, even if the charge was negative in any case.
Since the ocular surface is negatively charged, because of the presence of sialic acid residues in the mucus, some authors suggested that cationic NPs may better interact and/or penetrate cornea and conjunctiva than the anionic ones [97, 99] . For this reason, cationic gelatin NPs were prepared and loaded with a plasmid designed to encode human MUC5AC [100] . MUC5AC is a mucin protein that plays a role in the homeostasis of lacrimal fluid and is thus reduced in dry eye syndrome. NPs were prepared by ionic gelation technique starting from cationized gelatin; plasmid and an anionic polymer (chondroitin sulphate or dextran sulphate) were added to the cationic gelatine solution in the presence of tripolyphosphate. NPs obtained were characterized by a small size (less than 150 nm) and a positive surface charge (between +20 mV and +30 mV). The administration of associated plasmid NPs to rabbit cornea was followed by a an increase of the MUC5AC levels detected inside the precorneal tear film.
Gelatin NPs have been also proposed for intravitreal administration. In fact, freeze-dried gelatin NPs, obtained by UV cross-linking, were used as nanocarrier for basic fibroblast growth factor (bFGF) [68] (see also section 4.2). An electrostatic interaction occurred between negative gelatin and positive bFGF: the growth factor was released in vivo from the complex as a consequence of environmental changes, such as an increase of ionic strength and enzymatic degradation of gelatin. The study clearly demonstrated the ability of gelatin NPs to preserve bFGF from degradation, and, at the same time, to guarantee the anti-apoptotic effect thanks to a sustained release targeted to photoreceptors.
In the ophthalmic field, a recent example of nanoplatform based on elastin like polypeptide (ELP) was described for the intravitreal administration of a chaperone, as previously discussed in the present review [70] . Elastin like polypeptides are biopolymers derived from hydrophobic domain of tropoelastin, the soluble precursor of elastin. As well as tropoelastin, ELPs are soluble at low temperature, but, as a consequence of thermal raising, the solubility progressively decreases and self-assembly takes place [101] . Even if
ELPs are commonly known to be termoresponsive, they may be designed to react to other physical change, such as pH variation [102] . Several characteristics can be controlled, among which MW is surely the most important, especially when ELPs are intended for the preparation of platforms, or even nanoplatforms, for drug delivery. The use of recombinant silk-elastin like protein for NPs production was also reported [103] , even if not yet used for ocular formulations.
Peptides and proteins as functionalizing and coating agents
Finally, it is worth mentioning the role of proteins and peptides as active coating agents, that can enhance the cell adhesion and promote cell uptake. The idea, very simple but at the same time highly effective, consists in the conjugation of NPs with peptides or proteins, whose receptors are expressed on ocular tissues. Some examples are reported in the literature: among them, the conjugation of deslorelin and transferrin to polystirene NPs [33] . Deslorelin is a 1.3 kDa synthetic nonapeptide LHRH agonist, while transferrin is a glycoprotein having a MW of 80 kDa; they were chosen to functionalize NPs surface because of the expression of their receptors on both corneal epithelium and conjunctiva. In fact, the presence of specific receptors on ocular tissues justified the increase of the transport of conjugated NPs of approx. 70% across cornea ( Figure 5 ) and 50% through conjunctiva in an ex vivo bovine model, if compared to conventional NPs. A peptide active coating was also suggested to help the targeting of an anti-VEGF agent for the therapy of CNV, after intravenous injection of NPs: in fact, Luo et al. reported the use of the cell adhesion motif RGD tripeptide (arginine-glycine-aspartic acid) [104] . In this case the intravenous administration route was proposed as a valid alternative to the intravitreal injection of anti-VEGF, the latter procedure being poorly tolerated and sometimes injurious (see also section 3.2).
Finally, proteins can be useful in NPs preparation to promote physical stability and control the drug release rate. Some authors have suggested the use of albumin as coating agent of meloxicam nanocrystals (approx. average particle size 100 nm) intended for the treatment of postcataract endophthalmitis [87] . Furthermore, bovine serum albumin, as well as human serum albumin, showed stabilizing effects on therapeutic proteins when the NPs procedure involved an emulsification method [56] .
7 Future perspectives
Potential drug candidates
The number of therapeutic proteins proposed for the treatment of ocular diseases is constantly growing, thanks to the considerable contribution of biotechnology (Table 1) .
Among these, the newly developed therapeutic proteins are briefly detailed below.
Recombinant MP0112 is an anti-VEGF, belonging to DARPins, a new generation of designed low MW therapeutic proteins made by repeated ankyrin domains, that recently demonstrated its safety and bioactivity following intravitreal injection in the treatment of diabetic macular edema [105] and exudative AMD [106] .
Plasminogen kringle 5 (K5)
is an 80 amino-acids natural peptide having proved antiangiogenic properties, effective in prevention and block of retinal NV. After intravitreal administration, despite its effectiveness, it shows a very short half-life [107] . To minimize this low bioavailability, an expression plasmid of K5 was included in PLGA/chitosan NPs and then administered via injection in rats in vivo, with consequent K5 expression in all the layers of the retina [108] . Due to the high potential of the peptide, the possibility to prepare K5 loaded NPs should be take into account.
ESBA105 is a 26.3 kDa single chain variable region antibody fragment (scFv) direct against TNF-α. ESBA105 reached high concentration levels inside the anterior and posterior ocular tissues when topically applied in ex vivo and in vivo experiments performed on rabbits eye, thanks to both trans-corneal and trans-scleral permeation routes [109] . Recently, ESBA105 was successfully applied as eye drops in an in vivo study carried on human volunteers, reaching therapeutic levels inside anterior chamber, even if penetration inside the vitreous was low [110] . Even if no penetration enhancers are required [109, 110] , this scFv antibody should be considered a suitable candidate for NPs not to improve the permeation, which is quite high, rather to better control the amount permeated and to increase ESBA105 half-life inside ocular chambers, which is only 25 hours inside the vitreous [109] .
The neuroprotectant agent GDNF (glial cell line-derived neurotrophic factor) exerts a neuroprotective effect by increasing the retinal ganglion cells survival. Since PLGA microspheres intended for intravitreal delivery were developed and successfully administered to rats in vivo [111] , this positive result may suggest a similar desirable effect using NPs.
Recombinant human Hsp70 (rhHsp70) is a 72 kDa chaperone that has recently demonstrated its ability in prevent RPE degeneration, when studied in vitro on cellular lines [112] . In view of in vivo studies, the authors hypothesize that the formulation of the protein as NPs will provide a sustained release of the chaperone after intravitreal injection.
Carriers
Among animal proteins, casein and β-lactoglobulin from milk appear very promising carriers for drug delivery. Caseins constitute a family of four phosphoproteins (ranging in weight between 19 and 25 kDa), which appear very rich in proline residues, heat stable and amphiphilic, that can lead to formation of self-assembly micellar structures in aqueous solutions [113] . Casein has been already approved as excipient in tablet preparation and, as a consequence of its versatile physico-chemical properties, extensively used for the preparation of hydrogels, floating beads, microparticles [113] and more recently for nanoparticles [114] [115] [116] . Similarly, β-lactoglobulin, MW 18.4 kDa, is widely used in both pharmaceutical and nutraceutical fields and several examples of β-lactoglobulin NPs were reported [117] [118] [119] . Even if generally described as emergent nanocarriers, neither casein, nor β-lactoglobulin NPs has been yet proposed for ophthalmic administration, but certainly they deserve to be further investigated for this purpose. Legumin is a 360 kDa protein contained in peas. Proposed as carrier for NPs, thanks to the evidence that, by using the pH coacervation method, NPs of 250 nm in average diameter may be obtained [120] . Another possible source of carrier protein for NPs preparation is wheat gluten, from which the insoluble protein gliadin can be isolated; literature reports gliadin NPs intended for oral drug delivery [121] .
Soybean is a source of proteins, the so-called soy protein isolated (SPI), mainly consisting of two globular proteins, glycinin (360 kDa) and β-conglycinin (180 kDa). Since they show both hydrophilic and lipophylic properties, they are, at least in principle, suitable for active compounds having different properties [122] . As often noticeable for biopolymers, being SPI very versatile, it was proposed their use for realizing films, as devices for controlling the release of drugs [123] , and preparing NPs [124] , but also as nanosuspension stabilizers for poorly water-soluble compounds, in analogy with β-lactoglobulin [119] .
Nevertheless, to date no examples in ophthalmic delivery are available.
Finally, the relative small zein, a 38 kDa prolamine protein, contained in the seeds of maize, showing marked hydrophobic properties. Zein is commonly used in pharmaceutical technology field as tablet coating agent, tablet sealer, as well as wet granulation binder [95] and it has been studied as protein carrier starting from few years ago [125] [126] [127] , also in association with another protein, i.e. β-lactoglobulin [118] . However, no one has yet reported the use of zein-based NPs in ocular drug delivery. Even if no data for ocular application are available, in perspective, zein use could be take into account, being mucoadhesive, having a self-assembling nature and the ability to form both solid core and hollow NPs; furthermore, the possibility of loading biomacromolecules, such as proteins and peptides, and the protective effect exerted against enzymes have been already reported [125] . Gamma irradiation could be taken into account as effective sterilization technique [128] . 8 References
